Ligand validation:3B2R

VDN: 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE

VDN is a Ligand Of Interest in 3B2R designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3B2R_VDN_B_1	81%	9%	0.117	0.971	2.03	2.6	6	11	0	0	100%	1
3B2R_VDN_A_1	76%	9%	0.128	0.965	2.01	2.6	6	11	1	0	100%	1
1UHO_VDN_A_1000	63%	6%	0.155	0.95	2.52	2.85	11	10	2	0	100%	1
1XP0_VDN_A_201	78%	1%	0.109	0.951	3.54	4.88	9	16	0	0	100%	1
1XOT_VDN_A_101	43%	1%	0.18	0.903	3.4	4.84	8	23	4	0	100%	0.8

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.